NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Zimmer Biomet Holdings, Inc. ("Zimmer" or the "Company") (NYSE: ZBH). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at email@example.com or 212-697-6484. The investigation concerns whether Zimmer and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Zimmer designs, develops, manufactures and markets orthopaedics products, including knee, hip, shoulder, elbow, foot and ankle artificial joints and dental prostheses. On October 31, 2016 Zimmer stock dropped as much as 15% following the Company's announcement that it was reducing its full-year forecast for 2016 from a previous estimate of $7.71 billion, Zimmer now predicts revenues to be between $7.63 billion and $7.65 billion. If you are aware of any facts relating to this investigation, or purchased shares of Zimmer, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/zbh. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.